Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Guideline-recommended incorporation of biomarker testing results in metastatic colorectal cancer therapy.

Personalized medicine - 1 May 2020

Freml Jared, Delate Thomas, Hermosillo-Rodriguez Jesus

Abstract excerpt

Aim: To describe pharmacogenomic tumor testing among patients with metastatic colorectal cancer. Methods: This was a retrospective study of patients with metastatic colorectal cancer diagnosed between 1 January 2014 and 30 June 2018. Patients were assessed for pharmacogenomic testing and appropriateness of chemotherapy use. Results: Overall, 112/167 (67.1%) patients had at least one of the three recommended...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Biomarkers, Pharmacological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Colonic Neoplasms

Share to Guideline Adherence

Share to Neoplasm Metastasis

Share to Panitumumab

Share to Proto-Oncogene Mas

Source

Identifiers

PMID: 32330071
DOI: 10.2217/pme-2019-0107

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Guideline-recommended incorporation of biomarker testing results in metastatic colorectal cancer therapy.PMID 32330071Read ↗

Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database.Semantic proximity Read ↗

Assessing Oncologists' Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real-World Data.Semantic proximity Read ↗

Sociodemographic and clinical factors associated with receipt of biomarker testing in patients with metastatic colorectal cancer.Semantic proximity Read ↗

KRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis.Semantic proximity Read ↗

Biomarker Testing Disparities in Metastatic Colorectal CancerSemantic proximity Read ↗

Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg.Semantic proximity Read ↗

Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia.Semantic proximity Read ↗

Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary.Semantic proximity Read ↗

Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition.Semantic proximity Read ↗

Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition.Semantic proximity Read ↗

Impact of biomarkers and primary tumor location on the metastatic colorectal cancer first-line treatment landscape in five European countries.Semantic proximity Read ↗

Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.